AstraZeneca (AZN) to Release Quarterly Earnings on Tuesday

AstraZeneca (NASDAQ:AZN) is expected to release its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect AstraZeneca to post earnings of $1.09 per share and revenue of $15.4052 billion for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 6:45 AM ET.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.14 by $0.05. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter last year, the business posted $2.08 earnings per share. The firm’s revenue was up 12.0% on a year-over-year basis. On average, analysts expect AstraZeneca to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

AstraZeneca Trading Up 3.3%

Shares of AZN stock opened at $193.40 on Monday. The company has a market cap of $299.94 billion, a PE ratio of 64.25, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. AstraZeneca has a 1 year low of $122.48 and a 1 year high of $193.97. The stock’s 50 day simple moving average is $101.84 and its two-hundred day simple moving average is $88.64. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. CIBC Bancorp USA Inc. bought a new position in shares of AstraZeneca during the 3rd quarter worth $1,650,000. Centaurus Financial Inc. lifted its stake in AstraZeneca by 5.2% in the third quarter. Centaurus Financial Inc. now owns 7,419 shares of the company’s stock worth $569,000 after acquiring an additional 366 shares during the period. Advisory Services Network LLC lifted its stake in AstraZeneca by 1.3% in the third quarter. Advisory Services Network LLC now owns 20,191 shares of the company’s stock worth $1,549,000 after acquiring an additional 256 shares during the period. Hancock Whitney Corp grew its holdings in AstraZeneca by 1.8% during the 3rd quarter. Hancock Whitney Corp now owns 17,195 shares of the company’s stock worth $1,319,000 after acquiring an additional 299 shares in the last quarter. Finally, Abel Hall LLC increased its position in AstraZeneca by 4.1% during the 3rd quarter. Abel Hall LLC now owns 5,682 shares of the company’s stock valued at $436,000 after purchasing an additional 226 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AZN. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a report on Friday. HSBC restated a “buy” rating and issued a $108.00 target price on shares of AstraZeneca in a report on Wednesday, December 10th. Wall Street Zen downgraded shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Morgan Stanley reissued an “overweight” rating and issued a $103.00 price objective on shares of AstraZeneca in a research note on Wednesday, December 3rd. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating for the company. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.